An open multicenter phase II trial of weekly docetaxel for advanced-stage non-small-cell lung cancer in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study

Lung Cancer

Volumn 57, Issue 1, 2007, Pages 72-78

  LeCaer, Hervé ^a   Barlesi, Fabrice ^b   Robinet, Gilles ^c   Fournel, Pierre ^d   Geriniere, Laurence ^e   Bombaron, Pierre ^f   Falchero, Lionel ^g   Auliac, Jean Baptiste ^g   Crequit, Jacky ^h   Chouaid, Christos ⁱ  

^a Services de Pneumologie   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c CHU MORVAN   (France)

^d HÔPITAL NORD   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CH de Mulhouse   (France)

^g Service de Pneumologie Hia Laveran   (France)

^h Service de Pneumologie   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

Author keywords

Chemotherapy; Comorbidity; Elderly; Lung cancer; Phase II trial

Indexed keywords

DOCETAXEL;

AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; ELDERLY CARE; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; MALE; NAUSEA; NEOPLASM STAGING; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS; TIME FACTORS; VOMITING;

EID: 34249787037     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.02.012     Document Type: Article

References (36)

1. Balducci L. Lung cancer and aging. American Society of Clinical Oncology 2005 Educational Book; 587-591.
2. Jatoi A., Hillman S., Stella P.G., et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 9113-9119
3. Balducci L., and Extermann M. Management of cancer in older person: a practical approach. Oncologist 5 (2000) 224-227
4. Gridelli C., Aapro M., Ardizzoni A., et al. Treatment of advanced non-small cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 23 (2005) 3125-3137
5. Pfister D.G., Johnson D.H., Azzoli C.G., et al. Treatment of unresectable non-small-cell lung cancer guideline update 2003. J Clin Oncol 22 (2004) 330-353
6. Rossi A., and Gridelli C. Chemotherapy of advanced non-small-cell lung cancer in elderly patients. Ann Oncol 17 (2006) 58-60
7. LeCaer H., Delhoume J.Y., Thomas P.A., et al. Multicenter Phase II trial of carboplatin/vinorelbine in elderly patients with advanced NSCLC -efficacy and impact on quality of life: Groupe Français de PneumoCancérologie Study 9902. Clin Lung Cancer 7 (2005) 114-120
8. Frasci G., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J Clin Oncol 18 (2000) 2529-2536
9. Gridelli C., Perrone F., Gallo C., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomised trial. J Natl Cancer Inst 95 (2003) 362-372
10. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
11. Hainsworth J.D., Burris H.A., Litchy S., et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 89 (2000) 328-333
12. Gridelli C., Gallo C., Di Maio M., et al. A randomized clinical trial of two docetaxel regimens (weekly vs. 3 weeks) in the second-line treatment of non-small cell lung cancer. The DISTAL 01 Study Br J Cancer 91 (2004) 1996-2004
13. Lebitasy M.P., Monnet I., Depierre A., et al. Management of elderly lung cancer patients in France: a national prospective survey by the French Intergroup of Thoracic Oncology. Proc Am Soc Clin Oncol 765 (2004) 8163
14. Firat S., Byhardt R.W., Gore E., et al. Comorbidity and Karnofsky performance score in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 54 2 (2002) 357-364
15. Charlson M.E., Pompei P., Ales K.-L., et al. A new method of classifying prognostic comorbidity in longitudinal studies development and validation. J Chron Dis 40 (1987) 373-383
16. Frasci G. Chemotherapy of lung cancer in the elderly. Crit Rev Oncol Hematol 41 (2002) 349-361
17. Extermann M., Overcash J., Lyman G.H., et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998) 1582-1587
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
19. Spitzer W.O., Dobson A.J., Hall J., et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chron Dis 34 (1981) 585-587
20. Hollen P.J., Gralla R.J., Kris M.G., et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies.Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73 (1994) 2089-2098
21. Gehan E.A. The determinatio of the number of patients required in a preliminary and follow-up trial of new chemotherapeutic agent. J Chron Dis 13 (1961) 346-353
22. Hainsworth J.D. Practical aspects of weekly docetaxel administration schedules. Oncologist 9 (2004) 538-545
23. Camps C., Massuti B., Jimenez A., et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2006) 467-472
24. Chen Y.M., Shih J.F., Perng R.P., et al. A randomized trial of different docetaxel schedules in non- small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 129 (2006) 1031-1038
25. Rossi D., Graziano F., Ugolini M., et al. Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study. Tumori 90 (2004) 50-53
26. Bria E., Cuppone F., Ciccarese M., et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev 32 (2006) 583-587
27. Takagawi N., Segawa Y., Kishino D., et al. Clinical and pharmacokinetic study of docetaxel in elderly non small-cell lung cancer. Cancer Chemother. Pharmacol. 54 (2004) 230-236
28. Gridelli C., Manegold C., Mali P., et al. Oral vinorelbine given as monotherapy to advanced, elderly non-small-cell lung cancer: a multicenter phase II trial. Eur J Cancer 40 (2004) 2424-2431
29. Lilenbaum R. Treatment of elderly patients with advanced non-small cell lung cancer American Society of Clinical Oncology. Educational Book (2006) 468-470
30. Dujon C., Azarian R., Azarian V., et al. Lung cancer in the elderly: performance status and/or geriatric indice?. Rev Mal Respir 23 (2006) 307-318
31. Read W.L., Tierney R.M., Page N.C., et al. Differential prognostic impact of comorbidity. J Clin Oncol 22 (2004) 3099-3103
32. Aapro M., Kohne C.H., Cohen H.J., et al. Never too old? Age should be a barrier to enrollment in cancer clinical trials. Oncologist 10 (2005) 198-204
33. Extermann M., Meyer J., Me Ginnis M., et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Crit Rev Oncol Hematol 49 (2004) 69-75
34. Chodosh J., Petitti D.B., Elliot M., et al. Physician recognition of cognitive impairment: evaluating the need for improvement. J Am Geriatr Soc 52 (2004) 1051-1059
35. Extermann M., Aapro M.S., Bernabei R., et al. Use of comprehensive assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55 (2005) 241-252
36. Maione P., Perrone F., Gallo C., et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 23 (2005) 6865-6872